676 reports of this reaction
2.9% of all PEGASPARGASE reports
#3 most reported adverse reaction
FEBRILE BONE MARROW APLASIA is the #3 most commonly reported adverse reaction for PEGASPARGASE, manufactured by Servier Pharmaceuticals LLC. There are 676 FDA adverse event reports linking PEGASPARGASE to FEBRILE BONE MARROW APLASIA. This represents approximately 2.9% of all 23,600 adverse event reports for this drug.
Patients taking PEGASPARGASE who experience febrile bone marrow aplasia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE BONE MARROW APLASIA is a less commonly reported adverse event for PEGASPARGASE, but still significant enough to appear in the safety profile.
In addition to febrile bone marrow aplasia, the following adverse reactions have been reported for PEGASPARGASE:
FEBRILE BONE MARROW APLASIA has been reported as an adverse event in 676 FDA reports for PEGASPARGASE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE BONE MARROW APLASIA accounts for approximately 2.9% of all adverse event reports for PEGASPARGASE, making it one of the most commonly reported side effect.
If you experience febrile bone marrow aplasia while taking PEGASPARGASE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.